AAC Accepts, published online ahead of print on 28 October 2013
Antimicrob. Agents Chemother. doi:10.1128/AAC.00520-13

Comparative Efficacy and Safety of Vancomycin versus Teicoplanin in Patients with Healthcare-associated Methicillin-resistant *Staphylococcus aureus* Bacteremia: A Multi-center Prospective Observational Study

Running title: Efficacy of glycopeptides for MRSA bacteremia

Young Kyung Yoon,[a] Dae Won Park,[a] Jang Wook Sohn,[a] HyoYoul Kim,[b] Yeon-Sook Kim,[c] Chang-Seop Lee,[d] Mi Suk Lee,[e] Seong-Yeol Ryu,[f] Hee-Chang Jang,[g] Young Ju Choi,[h] Cheol-In Kang,[i] Hee Jung Choi,[j] Seung Soon Lee,[k] Shin Woo Kim,[l] Sang Il Kim,[m] Eu Suk Kim,[n] Jeong Yeon Kim,[o] Kyung Sook Yang,[p] Kyong Ran Peck,[i] Min Ja Kim[a]

Division of Infectious Diseases, Department of Internal Medicine, Korea University, College of Medicine[a]; Yonsei University Wonju College of Medicine[b]; Chungnam National University Hospital[c]; Chonbuk National University Medical School[d]; Kyung Hee University School of Medicine[e]; Keimyung University Dongsan Hospital[f]; Chonnam National University Medical School[g]; National Cancer Center[h]; Sungkyunkwan University School of Medicine[i]; Ewha Womans University School of Medicine[j]; Hallym University Sacred Heart Hospital[k]; Kyungpook National University Hospital[l]; Catholic University of Korea, College of Medicine[m]; Seoul National University Bundang Hospital[n]; Samyook Medical Center[o]; Department of Biostatistics[p], Korea University College of Medicine, Seoul, Republic of Korea

Keywords: methicillin-resistant *Staphylococcus aureus*, bacteremia, vancomycin, teicoplanin, treatment outcome

Corresponding author: Min Ja Kim, MD, PhD,

Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, Republic of Korea

Tel: +82-2-920-5685; Fax: +82-2-920-5616; E-mail: macropha@korea.ac.kr

Abstract

The purpose of this study was to compare the clinical efficacy and safety of vancomycin vs teicoplanin for the treatment of adult patients with healthcare-associated methicillin-resistant *Staphylococcus aureus* (HA-MRSA) bacteremia. A multi-center observational study was prospectively conducted in 15 teaching hospitals in Korea between February 2010 and July 2011. Adult patients (≥18 years) with HA-MRSA bacteremia who were initially treated with vancomycin (n = 134) or teicoplanin (n = 56) were enrolled. Clinical and microbiological responses and drug-related adverse events were compared between the 2 treatment groups using univariate and multivariate logistic regression analyses. The vancomycin or teicoplanin minimum inhibitory concentrations (MIC) were determined by E-test. The MRSA-related mortality, duration of fever, and duration of MRSA bacteremia between the 2 treatment groups were not significantly different. There was no significant difference in the occurrence of drug-related adverse events. Among the 190 MRSA isolates, the VAN MICs ranged 0.5 to 2 μg/mL (both MIC50 and MIC90, 1.5 μg/mL), and the TEC MIC ranged 0.5 to 8 μg/mL (MIC50, 3 μg/mL; MIC90, 6 μg/mL). In multivariate analyses, the antibiotic type, vancomycin or teicoplanin, was not associated with treatment outcomes. This study indicates that teicoplanin is an effective and safe alternative to vancomycin for the treatment of HA-MRSA bacteremia.

INTRODUCTION

Nosocomial bloodstream infections represent a major clinical challenge in many healthcare institutions worldwide despite laborious and costly infection control efforts. Healthcare-associated methicillin-resistant *Staphylococcus aureus* (HA-MRSA) bacteremia has imposed a distinctly high burden on medical expenses and considerable morbidity and mortality (1, 2).

Vancomycin (VAN) has widely been used for the treatment of MRSA infection over the past decades. Increasingly, however, therapeutic failures with VAN have been reported (3). There is also growing evidence of bacteremia caused by MRSA isolates with an increased VAN minimum inhibitory concentration (MIC) (4, 5). The VAN therapeutic monitoring guidelines in 2009 recommended more aggressive VAN dosing schemes, targeting VAN serum trough concentrations of 15–20 mg/L for MRSA bacteremia (6). Similarly, optimizing the pharmacokinetics of VAN to achieve an area under the curve (AUC)/MIC ratio $\geq$ 211 has been shown to predict more favorable treatment outcomes in cases of MRSA-associated complicated bacteremia (7). However, if the MRSA strains' MIC $\geq$ 2 μg/mL, conventional intermittent dosing might not achieve this ratio. Rather, it may increase nephrotoxicity (8).

Teicoplanin (TEC) is a glycopeptide antibiotic with an antibacterial spectrum similar to VAN, but is less toxic at daily doses of less than 800 mg (9, 10). It has a long half-life (45–70 hr), permitting once-daily dosing (11), and may enhance the intracellular killing of bacteria by phagocytes (12). TEC is commonly used for MRSA infections in Europe, while its use has not yet been approved in the USA. TEC has been used as an alternative agent for MRSA infections, however, there is a limited number of studies that have evaluated the clinical efficacy of TEC in patients with HA-MRSA bacteremia (13, 14).

71 The purpose of this prospective observational study was to compare the clinical efficacy
72 and safety of VAN vs TEC for the treatment of adult patients with HA-MRSA bacteremia.
73

74 ## METHODS

75 **Study design and patients.** A prospective, multi-center observational study was conducted in 15
76 teaching hospitals in the Republic of Korea over an 18-month period from February 2010 to July
77 2011. The subjects comprised hospitalized adult patients (≥18 years) with HA-MRSA bacteremia
78 who were initially treated with VAN (n = 134) or TEC (n = 56) and who were followed until
79 death or hospital discharge. Only the first episode of HA-MRSA bacteremia and the first blood
80 isolate of MRSA per patient that was susceptible to both VAN and TEC were included for
81 analysis. Patients with polymicrobial bacteremia were excluded in order for this study to evaluate
82 the impact of antibiotic therapy for MRSA bacteremia specifically.
83 A loading dose of VAN (1 g every 12 h) or TEC (400 mg every 12 h) was administered for
84 initial 24 h or 36 h, respectively, and then followed by daily maintenance doses of each drug that
85 were adjusted to the patient's renal function, if needed (15). In the 11 participating hospitals
86 (73.3%) that ran the therapeutic drug monitoring (TDM) practices for VAN, the TDM-guided
87 VAN dosing was performed, targeting serum trough levels between 15 and 20 μg/mL. None of
88 the participating hospitals ran the TDM for TEC. During the study period, there were no other
89 standardized interventions for the management of MRSA bacteremia, and physicians treated the
90 patients according to routine medical practice.

The study protocol was approved prior to study initiation by the institutional review boards at each participating hospital. As this observational study required no deviation from routine medical practice, the boards waived the need for informed consent.

Definitions. MRSA bacteremia was considered present if one or more blood cultures had positive results and if the clinical signs and course were consistent with MRSA infection (16).

The primary source of infection, based on the organs affected, was classified as one of the following: lower respiratory tract, intra-abdominal, genitourinary tract, skin and soft tissue, bone and joint infection, central nervous system, and catheter-related infection. Unknown origin of infection was defined as positive blood cultures without primary infection at another body site (16).

MRSA bacteremia was categorized epidemiologically as healthcare-associated or nosocomial. Community-onset MRSA bacteremia within ≤48 hours of hospital admission was considered healthcare-associated if, during the preceding 12 months, the patient had any of the following: admission to other hospitals or healthcare facilities for more than 2 days, surgery, dialysis, specialized home care, attention at day hospitals, or permanent indwelling catheters. Patients defined as having community-acquired infections were excluded from this study. Infections occurring in patients after 48 hours of hospital admission were considered nosocomial.

The duration of bacteremia after VAN or TEC treatment was calculated as the number of days from the start of MRSA treatment to the day the first negative blood culture was drawn. Sepsis, severe sepsis, and septic shock were defined according to the standard criteria (17). The community-acquired phenotype for the MRSA isolates was defined as being susceptible to clindamycin, erythromycin, and ciprofloxacin (18, 19).

The primary end point was clinical failure, defined as a composite of mortality attributable to MRSA bacteremia, microbiological failure, and/or persistent fever, except drug fever. Mortality attributable to MRSA bacteremia was defined as positive blood cultures for MRSA, persistent fever, and no other definite causes of death. Microbiological failure was defined as positive blood cultures for MRSA ≥7 days from the index culture under VAN or TEC therapy. Persistent fever was defined as ≥38.0°C for ≥7 days after the commencement of VAN or TEC treatment.

Variables. Physicians or research coordinators of the participating hospitals entered the clinical data of each patient into a standardized web-based case report form. An infectious disease doctor at the coordinating center checked the entered data and supported the study sites by sending queries throughout the study period. The parameters collected for this analysis included demographic characteristics, comorbid medical conditions, including Charlson's comorbidity index (20), factors predisposing to infections, primary source of MRSA bacteremia, Acute Physiology and Chronic Health Evaluation II (APACHE II) score (21) or Pitt's bacteremia score (22) at the onset of MRSA bacteremia, diagnosis of severe sepsis or septic shock, hospital mortality, and microbiological data.

Microbiological tests. Bacterial identification and antibiotic susceptibility were performed at each study site using a VITEK II (bioMérieux, Hazelwood, MO, USA) or MicroScan Pos Combo Panel Type 6 system (Baxter Diagnostics, West Sacramento, CA, USA). All MRSA isolates from participating hospitals were sent to the coordinating center. All isolates received

136 were immediately stored at -70 ℃ until August 2012 when microbiologic tests were performed
137 all at once. The VAN and TEC MICs for all 190 MRSA isolates were further determined by the
138 E-test (bioMérieux, Marcy l'Etoile, France) at the coordinating center according to the
139 manufacturer's instructions.
140
141 **Statistical analysis.** For comparisons between groups of continuous independent variables that
142 were normally distributed, the two-sample Student's t test was used. For comparisons of
143 continuous independent variables that were not normally distributed, the Mann-Whitney U test
144 was used. Summaries of the continuous variables were expressed as median and inter-quartile
145 range (IQR). Independent categorical variables were described using count (proportion) and
146 comparisons between groups were made using the Pearson's chi-square test or Fisher's exact test.
147 In the univariate analysis, the VAN or TEC MICs were evaluated as continuous variables as
148 well as categorical variables. The cut-off values of the VAN MICs and the TEC MICs were
149 determined with an analysis using the Chi-squared Automatic Interaction Detector (CHAID)
150 decision tree algorithm, to predict treatment outcome in the respective treatment group. The cut-
151 off values of the VAN MICs and the TEC MICs drawn from the CHAID algorithm were 1.5
152 μg/mL and 4.0 μg/mL respectively.
153 Multivariate logistic regression analyses using the backward stepwise variable selection
154 based on LR statistic was used to examine the impact of multiple independent predictors on the
155 clinical failure as a dependent variable. Trauma, renal diseases, hepatic diseases, pneumonia,
156 Pitt's bacteremia score, C-reactive protein, acute renal injury, duration of fever or bacteremia
157 after VAN or TEC treatment and antibiotic type were evaluated as independent variables for

multivariable logistic regression analysis if such independent variables were predictors of clinical failure at the 10% significance level. Hosmer–Lemeshow goodness-of-fit tests were performed to evaluate the models. Internal accuracy obtained by leave-one-out cross-validation was used to evaluate the performance of a predictive model. All tests were 2-tailed, and a *P*-value < 0.05 was considered statistically significant. All of the analyses were performed with IBM SPSS Statistics version 20.0 (IBM Corporation, Armonk, NY, USA), R 2.15.2 (The R Foundation for Statistical Computing, Vienna, Austria), and SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

RESUTLS

Patients and clinical characteristics. During the study period, 426 patients with HA-MRSA bacteremia were enrolled from the participating hospitals. Patients who were given antibiotics with no activity against MRSA isolates (n = 81) and 49 patients from whom MRSA isolates were not collected were excluded from the analysis. Patients who initially received other antibiotics before VAN or TEC (n = 96) and who received VAN or TEC for <3 days (n = 10) were also excluded. Eventually, 190 patients with HA-MRSA bacteremia who were initially treated with VAN (n = 134) or TEC (n = 56) for ≥3 days were included in this study.

The demographic and baseline characteristics of the 190 patients are listed in Table 1. Of these, 158 patients (83.2%) had nosocomial infections and 128 (67.4%) were male. The median age was 66 years (IQR, 51–74 years). The univariate analyses determined that there were no significant differences in sex, age, and category of infection between the VAN and TEC treatment groups (Table 1).

The most common source of MRSA bacteremia was catheter-related infections (47.9%), followed by pneumonia (14.7%), surgical wounds (10.0%), and bone and joint infections (5.8%). The univariate analyses revealed no significant differences in the primary source of infection between the 2 treatment groups, except for intra-abdominal infections (Table 1).

The median Charlson's comorbidity index was 2 (IQR, 1–4), and univariate analyses determined that the VAN group had a significantly higher Charlson's comorbidity index than the TEC group. Particularly, underlying malignancy and hematologic diseases were significantly more common in the VAN group than the TEC group (Table 1). Sixty-six patients (34.7%) had severe sepsis or septic shock, and the median APACHE II score at the onset of HA-MRSA bacteremia was 17 (IQR, 12–21). There was no significant difference in the APACHE II score of HA-MRSA bacteremia between the 2 treatment groups (Table 1).

Microbiological characteristics. All 190 MRSA isolates underwent microbiological analysis. The VAN MIC range was 0.5–2 μg/mL; and the VAN MIC_{50} and MIC_{90} were both 1.5 μg/mL. The TEC MIC range was 0.5–8 μg/mL; and the TEC MIC_{50} and MIC_{90} were 3 μg/mL and 6 μg/mL, respectively. Distribution of the VAN and TEC MICs and the antibiotic phenotype among the MRSA isolates were shown by the treatment group and treatment outcome in Table 2. In a total of 190 patients analyzed, the VAN or TEC MICs were not associated with clinical failure.

When evaluated the influences of the VAN MICs on clinical outcomes in the VAN-treated group, a VAN MIC ≥ 1.5 μg/mL was the significant risk factor for in-hospital mortality (VAN MIC < 1.5 μg/mL vs ≥1.5 μg/mL; 19.1% [9/47] vs 41.4% [36/87], $P = 0.009$), but not for

clinical failure (40.4% [19/47] vs 34.5% [30/87], $P = 0.495$). In the TEC-treated group, a TEC MIC ≥ 4 μg/mL in the TEC group was not significantly associated with treatment failure (TEC MIC < 4 μg/mL vs ≥4 μg/mL; 53.3% [24/45] vs 45.5% [5/11], $P = 0.639$) or in-hospital mortality (40.0% [18/45] vs 27.3% [3/11], $P = 0.508$).

The proportion of MRSA isolates with phenotypic expression of community-acquired MRSA was 16.3% (31/190) and was not significantly different between the 2 treatment groups (Table 2).

Treatment outcomes. The overall all-cause in-hospital mortality and MRSA-related mortality were 34.7% (66/190) and 14.7% (28/190), respectively. There were no significant differences in the all-cause in-hospital mortality and MRSA-related mortality between the 2 treatment groups. After the commencement of VAN or TEC therapy, a significant difference was not exhibited for the duration of fever and MRSA bacteremia between the 2 treatment groups (Table 3). The median durations of VAN or TEC treatment showed no significant differences (median [IQR], 14 days [IQR, 9–23 days] vs 13 days [IQR, 8–21 days], $P = 0.239$).

In total, 36 patients (18.9%) received alternative drugs due to poor clinical response (n = 23), drug-related adverse events (n = 12), or other reasons (n = 4). In the VAN group, VAN was switched with alternative antibiotics in 20 patients (14.9%): TEC (n = 11), linezolid (n = 6), tigecycline (n = 2), or levofloxacin plus rifampin (n = 1). In the TEC group, 16 patients (28.6%) received alternative antibiotics: VAN (n = 9), linezolid (n = 4), an aminoglycoside (n = 1), clindamycin (n = 1), or trimethoprim/sulfamethoxazole plus rifampin (n = 1).

The median duration of VAN in alternation from VAN to TEC (n = 11) and vice versa (n = 9) was 9 days (IQR, 6-17 days) and 10 days (IQR, 7-13 days), respectively.

There was no significant difference in the occurrence of drug-related adverse events between the 2 treatment groups (20.9% [28/134] vs 14.3% [8/56], $P = 0.289$) (Table 3). Among the 8 patients who received alternative glycopeptides due to drug-related adverse events, cross-reactivity was not observed between VAN and TEC. One patient with VAN-induced acute kidney injury developed TEC-induced neutropenia.

In the multiple logistic regression modeling, the antibiotic type (VAN or TEC) was not an independent risk factor for clinical failure in the patients with HA-MRSA bacteremia, regardless of variable selection (Table 4). The statistically significant factors associated with clinical failure included Pitt's bacteremia score (odds ratio, OR, 1.51; 95% confidence interval, CI, 1.10–2.06), acute renal injury (OR, 15.99; 95% CI, 1.81–141.16), duration of fever (OR, 1.77; 95% CI, 1.36–2.32), and duration of bacteremia (OR, 1.76; 95% CI, 1.34–2.31) (Table 4). The *P*-values for the Hosmer–Lemeshow goodness-of-fit test were greater than 0.05. Hence, there is no significant evidence of lack of fit for any of the final models.

Leave-one-out cross-validation was performed to assess the predictive accuracy of each final model. The AUCs for the clinical failure model were greater than 0.90 for both the raw data set and leave-one-out cross-validation. For this mode, the sensitivity, specificity, positive predictive value, and negative predictive value obtained with an optimal cut-off point were greater than 0.80 (Fig. 1).

DISCUSSION

This multi-center prospective study compared the clinical efficacy and safety of VAN vs TEC for the treatment of adult patients with HA-MRSA bacteremia in hospital settings where MRSA

247 prevalence was about 70% (23). This study found that TEC has comparable efficacy and safety
248 to VAN for the treatment of HA-MRSA bacteremia.

249 The in-hospital mortality rate of HA-MRSA bacteremia in the VAN and TEC treatment
250 groups of this study were 33.6% and 37.5%, respectively, which is comparable to the range of
251 14%–60% reported previously in other studies (3, 24-26). Based on the Charlson comorbidity
252 index or Pitt's bacteremia score, the clinical severity of the patients in our study was comparable
253 to those of healthcare-associated or community-acquired MRSA infections (14, 26). In addition,
254 4 risk factors for clinical failure of HA-MRSA bacteremia, namely the Pitt's bacteremia score,
255 acute renal injury, duration of fever, and bacteremia, were not different from those reported
256 previously (26-29).

257 In this study, the type of glycopeptide, i.e., VAN or TEC, was not the risk factor associated
258 with clinical failure. Meta-analysis studies have reported that there were no differences in
259 clinical cure, microbiological cure, and mortality between VAN and TEC treatments for Gram-
260 positive infections, including bacteremia, pneumonia, febrile neutropenia, and skin and soft
261 tissue infections (10, 30, 31). However, studies on the comparative efficacy of VAN vs TEC
262 against MRSA bacteremia (13, 32, 33) are still limited. Liu et al. (33) demonstrated that TEC
263 was as efficacious as VAN in terms of treatment success rate for MRSA bacteremia (TEC group,
264 85% [17/20] vs VAN group, 75% [15/20], $P = 0.69$). On the other hand, Huang et al. (32)
265 reported that there was no statistically significant difference in the hospital mortality rate (42%
266 vs 47%) and microbiological failure rate (34% vs 40%) between the VAN group ($n = 36$) and the
267 TEC group ($n = 15$) among patients with MRSA infective endocarditis.

268 In this study, there was no significant difference in the occurrence of drug-related adverse
269 events between the VAN and TEC treatment groups. In meta-analysis studies, the incidence of

total drug-related adverse events, including nephrotoxicity and red man syndrome, was lower with TEC (10, 30, 31). This discrepancy might have resulted from the closed TDM of VAN in our study, carried out according to recent clinical practice guidelines (34). On the other hand, the dosing of TEC was administered as guided in the package insert because TDM of TEC is not routinely available.

In this study, the use of an alternative agent, i.e., from VAN to TEC, or vice versa, was common in the patients with HA-MRSA bacteremia due to the reimbursement system in Korea. VAN was switched for TEC as an alternative agent, or vice versa, in 20 (14.9%) and 16 patients (28.6%), respectively. Lin et al. (13) reported no significant difference in 30-day mortality among 3 treatment groups of elderly patients with persistent MRSA bacteremia (VAN vs TEC vs VAN/TEC alternately, 59.6% [65/109] vs 50.0% [7/14] vs 65.5% [19/29]). They also reported that alternation between VAN and TEC treatment was not more effective than either VAN or TEC treatment alone (13). However, the appropriateness of this alternative therapy needs to be evaluated in prospective randomized controlled trials. Antibiotics such as linezolid or daptomycin as promising salvage agents or a novel strategy of combined antibiotic treatment should be considered for better treatment outcomes of HA-MRSA bacteremia (27, 35).

In our study, the cross-adverse reactions between VAN and TEC were not remarkable, although a limited number of cases were evaluated. Previous studies have reported that the alternate use of TEC in cases of VAN intolerance was associated with a high incidence of drug-related adverse events, most notably neutropenia (36, 37). Therefore, the potential cross-reactivity between these 2 glycopeptides remains to be clarified in future studies.

In recent meta-analysis studies, VAN MICs of $\geq$ 1.5 μg/mL or $\geq$ 2.0 μg/mL are associated with increased mortality as well as clinical failure among patients with MRSA infections (4, 38).

In this study, the VAN MICs of ≥ 1.5 μg/mL from the VAN-treated group or the TEC MICs of ≥ 4.0 μg/mL from TEC-treated group were more common in the non-survivors compared to the survivors, but not a significant factor for clinical failure. These findings indicate that the thresholds VAN or TEC MICs for clinical outcomes might be different among the study populations.

This study has some limitations. First, this prospective study was not designed to include the detailed complications associated with MRSA bacteremia. This may have resulted in a falsely low complication rate. However, catheter-related infections accounted for 47.9% of the HA-MRSA bacteremia in this study, which were easily controlled with catheter removal and antibiotic therapy. Thus, the related confounding factors might be minimal. Second, this was not a randomized clinical trial: the doctors chose VAN to initiate treatment due to the reimbursement system in Korea. Therefore, the patients who received TEC therapy may not be representative of the larger population with HA-MRSA bacteremia. Third, individualized dosing regimens of VAN or TEC relative to the MICs were not undertaken in this study. Implementation of the individualized VAN dosing approach targeting an AUC/MIC ratio of 400 mcg•h/mL or greater, rather than a trough serum concentration, may lead to improved clinical outcomes in critically ill patients (39). Lastly, other antibiotics switched from VAN or TEC, or concomitant antibiotics with VAN or TEC might have influenced the treatment outcome. The clinical effect of these antibiotics failed to be evaluated owing to the small number of study cases.

In conclusion, this multi-center prospective study indicates that TEC is an effective and safe alternative to VAN for the treatment of HA-MRSA bacteremia. Further studies that take the

AUC/MIC ratio of VAN and TEC into account may be required for better clinical outcomes in treating patients with HA-MRSA bacteremia.

ACKNOWLEDGMENTS

This work was supported by a grant (A102065) from the Korean Health 21 R&D project of the Ministry for Health, Welfare and Family Affairs, Republic of Korea.

The authors have no conflicts of interest.

REFERENCES

1. **Primo MG, Guilarde AO, Martelli CM, Batista LJ, Turchi MD.** 2012. Healthcare-associated Staphylococcus aureus bloodstream infection: length of stay, attributable mortality, and additional direct costs. Braz. J. Infect. Dis. **16:**503-509.
2. **Park SY, Son JS, Oh IH, Choi JM, Lee MS.** 2011. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection **39:**141-147.
3. **Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC, Jr.** 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. **38:**1700-1705.
4. **Jacob JT, Diazgranados CA.** 2013. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int. J. Infect. Dis. **17:**e93-e100.
5. **van Hal SJ, Lodise TP, Paterson DL.** 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. **54:**755-771.
6. **Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP.** 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. **49:**325-327.
7. **Brown J, Brown K, Forrest A.** 2012. Vancomycin AUC24/MIC ratio in patients with

complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob. Agents Chemother. **56:**634-638.

8. **Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL.** 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. **49:**507-514.

9. **Verbist L, Tjandramaga B, Hendrickx B, Van Hecken A, Van Melle P, Verbesselt R, Verhaegen J, De Schepper PJ.** 1984. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. **26:**881-886.

10. **Svetitsky S, Leibovici L, Paul M.** 2009. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob. Agents Chemother. **53:**4069-4079.

11. **Williams AH, Gruneberg RN.** 1988. Teicoplanin revisited. J. Antimicrob. Chemother. **22:**397-401.

12. **Pedrera MI, Barriga C, Rodriguez AB.** 1995. Intracellular activity of both teicoplanin and vancomycin against Staphylococcus aureus in human neutrophils. Comp. Immunol. Microbiol. Infect. Dis. **18:**123-128.

13. **Lin SH, Lai CC, Tan CK, Liao WH, Hsueh PR.** 2011. Comparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int. J. Antimicrob. Agents **37:**179-181.

14. **Chang HJ, Hsu PC, Yang CC, Siu LK, Kuo AJ, Chia JH, Wu TL, Huang CT, Lee MH.** 2012. Influence of teicoplanin MICs on treatment outcomes among patients with

teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study. J. Antimicrob. Chemother. **67:**736-741.

15. **Gilbert DN, Moellering RC, Jr., Eliopoulos GM (ed.).** 2010. The Sanford guide to antimicrobial therapy 2010, 40th ed. Antimicrobial Therapy, Sperryville, VA.

16. **Horan TC, Andrus M, Dudeck MA.** 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control **36:**309-332.

17. **Longo DL, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J.** 2012. Harrison's principles of internal medicine, 18th ed. McGraw-Hill, New York.

18. **O'Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA, Monk A, Said-Salim B, Kreiswirth BN, Grubb WB.** 2004. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J. Clin. Microbiol. **42:**3185-3190.

19. **David MZ, Glikman D, Crawford SE, Peng J, King KJ, Hostetler MA, Boyle-Vavra S, Daum RS.** 2008. What is community-associated methicillin-resistant Staphylococcus aureus? J. Infect. Dis. **197:**1235-1243.

20. **Charlson M, Szatrowski TP, Peterson J, Gold J.** 1994. Validation of a combined comorbidity index. J. Clin. Epidemiol. **47:**1245-1251.

21. **Knaus WA, Draper EA, Wagner DP, Zimmerman JE.** 1985. APACHE II: a severity of disease classification system. Crit. Care Med. **13:**818-829.

22. **Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL.** 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. **115:**585-590.

23. **Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH,**

Chong Y. 2011. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med. J. **52:**793-802.

24. **Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y.** 2003. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. **36:**53-59.

25. **Moore CL, Lu M, Cheema F, Osaki-Kiyan P, Perri MB, Donabedian S, Haque NZ, Zervos MJ.** 2011. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool. Antimicrob. Agents Chemother. **55:**4581-4588.

26. **Hall RG, 2nd, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA, Brouse SD, Bell T, Bedimo RJ, Alvarez CA.** 2012. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect. Dis. **12:**104.

27. **Lin SH, Liao WH, Lai CC, Liao CH, Tan CK, Wang CY, Huang YT, Hsueh PR.** 2010. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J. Antimicrob. Chemother. **65:**1792-1798.

28. **Liao CH, Chen SY, Huang YT, Hsueh PR.** 2008. Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan. Int. J. Antimicrob. Agents **32:**326-332.

29. **Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC.** 2010. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the

impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect. Dis. **10:**159.

30. **Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E.** 2010. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev**:**CD007022.

31. **Wood MJ.** 1996. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. **37:**209-222.

32. **Huang JH, Hsu RB.** 2008. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study. Scand. J. Infect. Dis. **40:**462-467.

33. **Liu C-Y, Lee W-S, Fung C-P, Cheng N-C, Liu C-L, Yang S-P, Chen S-L.** 1996. Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia. Clin. Drug Investig. **12:**80-87.

34. **Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA, Chambers HF.** 2011. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. **52:**285-292.

35. **Park HJ, Kim SH, Kim MJ, Lee YM, Park SY, Moon SM, Park KH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS.** 2012. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J. Infect. **65:**505-512.

36. **Hsiao SH, Chou CH, Lin WL, Lee EJ, Liao LH, Chang HJ, Yeh PY, Lin CY, Wu TJ.**

2012. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J. Clin. Pharm. Ther. **37:**296-300.

37. **Hung YP, Lee NY, Chang CM, Lee HC, Wu CJ, Chen PL, Lee CC, Chung CH, Ko WC.** 2009. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review. Clin. Ther. **31:**1977-1986.

38. **van Hal SJ, Lodise TP, Paterson DL.** 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. **54**:755-771.

39. **DeRyke CA, Alexander DP.** 2009. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration–time curve/minimum inhibitory concentration. Hosp. Pharm. **44**:751–765.

451 **TABLE 1** Demographic and baseline characteristics of 190 patients with MRSA bacteremia according to treatment group and
452 outcome

		Treatment group			Treatment outcome		
Variables	All (*n*=190)	Vancomycin (*n*=134)	Teicoplanin (*n*=56)	*P*-value	Success (*n*=112, 58.9%)	Failure (*n*=78, 41.1%)	*P*-value
Antibiotic type (vancomycin), n (%)	134 (70.5)	134 (100)	0	<0.001	85 (75.9)	49 (62.8)	0.052
Male, n (%)	128 (67.4)	92 (68.7)	36 (64.3)	0.558	78 (69.6)	50 (64.1)	0.423
Median age, years (IQR)	66 (51,73)	64.5 (51,73)	68 (51.5,74)	0.521	65 (52,72)	67.5 (50,76)	0.508
Time of bacteremia, n (%)							
≤48 hr	42 (25.6)	35 (26.1)	7 (23.3)	0.752	28 (26.9)	14 (23.3)	0.612
>48 hr	122 (74.4)	99 (73.9)	23 (76.7)		76 (73.1)	46 (76.7)	
Category of infection, n (%)							
Healthcare-associated	32 (16.8)	23 (17.2)	9 (16.1)	0.854	20 (17.9)	12 (15.4)	0.654
Nosocomial	158 (83.2)	111 (82.8)	47 (83.9)		92 (82.1)	66 (84.6)	
Comorbid illness, n (%)							

Cardiovascular	97 (51.1)	65 (48.5)	32 (57.1)	0.278	54 (48.2)	43 (55.1)	0.348
Central nervous system	47 (24.7)	33 (24.6)	14 (25.0)	0.957	31 (27.7)	16 (20.5)	0.260
Malignancy	57 (30.0)	47 (35.1)	10 (17.9)	0.018	36 (32.1)	21 (26.9)	0.440
Trauma	18 (9.5)	12 (9.0)	6 (10.7)	0.706	5 (4.5)	13 (16.7)	0.005
Renal	39 (20.5)	28 (20.9)	11 (19.6)	0.845	18 (16.1)	21 (26.9)	0.068
Hepatic	20 (10.5)	17 (12.7)	3 (5.4)	0.133	16 (14.3)	4 (5.1)	0.043
Respiratory	23 (12.1)	16 (11.9)	7 (12.5)	0.914	10 (8.9)	13 (16.7)	0.108
Solid organ or bone marrow transplant	4 (2.1)	3 (2.2)	1 (1.8)	1.000	3 (2.7)	1 (1.3)	0.645
Metabolic	66 (34.7)	48 (35.8)	18 (32.1)	0.627	34 (30.4)	32 (41.0)	0.129
HIV	2 (1.1)	2 (1.5)	0	1.000	1 (0.9)	1 (1.3)	1.000
Hematologic	30 (15.8)	26 (19.4)	4 (7.1)	0.035	19 (17.0)	11 (14.1)	0.595
Gastrointestinal bleeding	8 (4.2)	5 (3.7)	3 (5.4)	0.695	3 (2.7)	5 (6.4)	0.276
Charlson's comorbidity index, median (IQR)	2 (1–4)	3 (1–4)	1 (0–3)	0.008	2 (0–4)	2 (1–4)	0.693
Primary source of bacteremia, n (%)							

Catheter-related infection	91 (47.9)	70 (52.2)	21 (37.5)	0.064	59 (52.7)	32 (41.0)	0.114
Pneumonia	28 (14.7)	19 (14.2)	9 (16.1)	0.737	10 (8.9)	18 (23.1)	0.007
Surgical wound infection	19 (10.0)	13 (10.4)	5 (8.9)	0.750	13 (11.6)	6 (7.7)	0.376
Bone and joint infection	11 (5.8)	10 (7.5)	1 (1.8)	0.179	5 (4.5)	2 (2.6)	0.702
Intra-abdominal infection	10 (5.3)	3 (2.2)	7 (12.5)	0.008	3 (2.7)	4 (5.1)	0.448
Urinary tract infection	7 (3.7)	3 (2.2)	4 (7.1)	0.198	7 (6.2)	4 (5.1)	1.000
Skin and soft tissue infection	7 (3.7)	5 (3.7)	2 (3.6)	1.000	1 (0.9)	3 (3.8)	0.307
Cardiovascular infection	4 (2.1)	2 (1.5)	2 (3.6)	0.583	5 (4.5)	5 (6.4)	0.743
Central nervous system infection	1 (0.5)	1 (0.7)	0	1.000	0	1 (1.3)	0.411
Head and neck infection	1 (0.5)	0	1 (1.8)	0.295	1 (0.9)	0	1.000
Unknown	11 (5.8)	7 (5.2)	4 (7.1)	0.734	8 (7.1)	3 (3.8)	0.530
Clinical severity at the onset of MRSA bacteremia, n (%)							
Fever (≥38.0°C)	142 (74.7)	104 (77.6)	38 (67.9)	0.158	90 (80.4)	52 (66.7)	0.033
SIRS	189 (99.5)	133 (99.3)	56 (100)	1.000	111 (99.1)	78 (100)	1.000
Development of severe	66 (34.7)	43 (32.1)	23 (41.1)	0.236	31 (27.7)	35 (44.9)	0.014

sepsis or septic shock							
Pitt's bacteremia score, median (IQR)	1 (0–3)	1 (0–3)	1 (0–4)	0.542	1 (0–3)	2 (0–3)	0.286
APACHE II score, mean ± SD	17 (12-21)	15 (12-21)	19 (13-23)	0.211	17 (11–21)	17 (13–21)	0.667
APACHE II score ≥ 20	42 (33.3)	23 (32.9)	19 (33.9)	0.899	22 (30.6)	20 (37.0)	0.445
Complicated condition							
Foreign body retention	8 (4.2)	7 (5.2)	1 (1.8)	0.440	7 (6.2)	1 (1.3)	0.144
Infective endocarditis	5 (2.6)	4 (3.0)	1 (1.8)	1.000	3 (2.7)	2 (2.6)	1.000
Metastatic infections[a]	11 (5.8)	9 (6.7)	2 (3.6)	0.512	8 (7.1)	3 (3.8)	0.530
Laboratory findings at the onset of MRSA bacteremia, n (%)							
C-reactive protein (mg/L)	10.8 (4.8–22.1)	11.1 (5.2–20.2)	9.9 (4.1–23.0)	0.914	9.2 (3.9–17.4)	14.3 (6.8–24.4)	0.039
Hematocrit < 30%	98 (51.6)	66 (49.3)	32 (57.1)	0.321	53 (47.3)	45 (57.7)	0.159
Platelet < 100,000/μL	41 (21.6)	30 (22.4)	11 (19.6)	0.675	22 (19.6)	19 (24.4)	0.437
Albumin < 3.0 g/dL	84 (44.2)	56 (41.8)	28 (50.0)	0.299	49 (43.8)	35 (44.9)	0.878

Total bilirubin ≥ 2.0 mg/dL	37 (19.5)	27 (20.1)	10 (17.9)	0.716	20 (17.9)	17 (21.8)	0.500
Creatinine ≥ 2.0 mg/dL	52 (27.4)	37 (27.6)	15 (26.8)	0.907	33 (29.5)	19 (24.4)	0.272
Serum sodium < 130.0 mmol/L	17 (8.9)	15 (11.2)	2 (3.6)	0.093	13 (11.6)	4 (5.1)	0.124

453 HIV, Human immunodeficiency virus; SIRS, systemic inflammatory response syndrome; IQR, inter-quartile range; APACHE II,
454 Acute Physiology and Chronic Health Evaluation II; SD, standard deviation; MRSA, methicillin-resistant *Staphylococcus aureus*
455 [a]Sites of metastatic infections include bones and joints, the epidural space, intervertebral disks, heart valves, and intra-abdominal
456 organs.
457

458 **TABLE 2** Microbiological characteristics of 190 patients with MRSA bacteremia according to treatment group and outcome

		Treatment group			Treatment outcome		
Variables	All (*n*=190)	Vancomycin (*n*=134)	Teicoplanin (*n*=56)	*P*-value	Success (*n*=112, 58.9%)	Failure (*n*=78, 41.1%)	*P*-value
MIC, µg/mL							
Vancomycin, median (IQR)	1.5 (1.0-1.5)	1.5 (1.0-1.5)	1.0 (1.0-1.5)	<0.001	1.5 (1.0-1.5)	1.5 (1.0-1.5)	0.324
Teicoplanin, median (IQR)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	3.0 (2.0-3.0)	0.039	3.0 (2.0-4.0)	3.0 (2.0-4.0)	0.476
Vancomycin, n(%)							
MIC ≥ 1.5 µg/mL	106 (55.8)	87 (64.9)	19 (33.9)	0.001	67 (59.8)	39 (50.0)	0.180
Teicoplanin, n(%)							
MIC ≥ 4 µg/mL	64 (33.7)	53 (39.6)	11 (19.6)	0.008	42 (37.5)	22 (28.2)	0.182
CA-MRSA phenotype, n(%)[12,13]	31 (16.3)	25 (18.7)	6 (10.7)	0.101	21 (18.8)	10 (12.8)	0.199

459 MIC, Minimum inhibitory concentration; CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*

460

461 **TABLE 3** Antibiotic treatment outcomes and the related adverse events of 190 patients with healthcare-associated MRSA

462 bacteremia

	Treatment group				Treatment outcome		
Variables	All (*n* = 190)	Vancomycin (*n* = 134)	Teicoplanin (*n* = 56)	*P*-value	Success (*n*=112, 58.9%)	Failure (*n*=78, 41.1%)	*P*-value
Antibiotic treatment, n (%)							
Interval from culture to VAN or TEC treatment ≥ 48 hr	64 (41.8)	42 (39.3)	22 (47.8)	0.324	38 (40.9)	26 (43.3)	0.762
Duration of VAN or TEC treatment (days), median (IQR)	14 (3,23)	14 (9,23)	13 (8,21)	0.239*	14 (9,21)	13 (8,24)	0.995*
Clinical response, n (%)							
Duration of bacteremia after VAN or TEC	1 (0,2)	1 (0,2)	0 (0,1)	0.254*	0 (1,0)	1 (0,7)	<0.001*

treatment (days), median (IQR)							
Bacteremia ≥ 7 days after VAN or TEC treatment	20 (10.9)	15 (11.7)	5 (9.1)	0.601	0	20 (25.6)	<0.001
Duration of fever after VAN or TEC treatment (days), median (IQR)	4 (2,7)	4 (2,6)	5 (2,11)	0.084*	3 (2,5)	8 (4,17)	<0.001*
Fever ≥ 7 days after VAN or TEC treatment	51 (29.5)	29 (24.0)	22 (42.3)	0.015	0	51 (67.1)	<0.001
Drug-related adverse events during treatment, n (%)	36 (18.9)	28 (20.9)	8 (14.3)	0.289	19 (17.0)	17 (21.8)	0.403
Acute renal injury	17 (8.9)	14 (10.4)	3 (5.4)	0.262	6 (5.4)	11 (14.1)	0.038
Hepatotoxicity	3 (1.6)	1 (0.7)	2 (3.6)	0.208*	3 (2.7)	0	0.270*
Bone marrow toxicity	10 (5.3)	8 (6.0)	2 (3.6)	0.726*	8 (7.1)	2 (2.6)	0.202*

Fever	8 (4.2)	6 (4.5)	2 (3.6)	1.000*	5 (4.5)	3 (3.8)	1.000*
Rash	1 (0.5)	1 (0.7)	0	1.000*	0	1 (1.3)	0.411*
Change of initial antibiotics, n (%)	36 (18.9)	20 (14.9)	16 (28.6)	0.029	17 (15.2)	19 (24.4)	0.112
Outcome							
Hospital stay after bacteremia (days), median (IQR)	23 (11,49)	23 (12,49)	25 (9,52)	0.706*	23 (10,47)	24 (12,53)	0.867*
In-hospital mortality, n (%)	66 (34.7)	45 (33.6)	21 (37.5)	0.605	27 (24.1)	39 (50.0)	<0.001
Mortality attributable to MRSA, n (%)	28 (14.7)	18 (13.4)	10 (17.4)	0.433	0	28 (35.9)	<0.001

463 IQR, Inter-quartile range; VAN, vancomycin; TEC, teicoplanin; MRSA, methicillin-resistant *Staphylococcus aureus*

464 **TABLE 4** Multivariable logistic regression analysis of risk factors associated with clinical failure in the 190 patients with MRSA
465 bacteremia

	Multivariate logistic regression analysis without variable selection		Multivariate logistic regression with backward variable selection based on LR	
Independent variable	OR (95% CI for OR)	*P*-value	OR (95% CI for OR)	*P*-value
Antibiotic type (vancomycin)	0.73 (0.18, 2.98)	0.666		
Trauma (yes)	7.38 (0.85, 63.77)	0.069		
Renal (yes)	1.62 (0.39, 6.76)	0.509		
Hepatic (yes)	1.09 (0.12, 10.21)	0.939		
Pneumonia (yes)	1.94 (0.43, 8.78)	0.391		
Pitt's bacteremia score	1.60 (1.13, 2.26)	0.008	1.51 (1.10, 2.06)	0.010
C-reactive protein	1.00 (0.99, 1.02)	0.740		
Acute renal injury (yes)	18.41 (1.76, 192.26)	0.015	15.99 (1.81, 141.16)	0.013
Duration of fever (days)	1.78 (1.34, 2.37)	<0.001	1.77 (1.36, 2.32)	<0.001
Duration of bacteremia (days)	1.83 (1.34, 2.48)	<0.001	1.76 (1.34, 2.31)	<0.001

466 LR, Logistic regression analysis; OR, odds ratio; 95% CI, 95% confidence interval

467



468

469

470 **FIG 1** Receiver operating characteristic curve for clinical failure obtained using the predictive

471 probability of multivariate logistic regression model and validation results.

472

Variable	Validation	AUC	Sensitivity, %	Specificity, %	PPV, %	NPV, %
Clinical failure	Validation for raw data set	0.939 (0.903–0.974)	84.2 (74.0–91.6)	90.4 (82.6–95.5)	87.7 (78.1–93.5)	87.6 (79.1–94.1)
	Leave-one-out cross-validation	0.926 (0.876–0.961)	80.3 (69.5–88.5)	91.5 (83.9–96.3)	88.4 (78.4–94.9)	85.1 (76.6–91.5)

473 AUC, Area under the curve; PPV, positive predictive value; NPV, negative predictive value; MRSA, methicillin-resistant

474 *Staphylococcus aureus*

475 *The above values except AUC are denoted by optimal values in each final model